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the malignant pleural effusions
Rong Biaoxue1, Ma Shuxia2, Gao Wenlong3 and Yang Shuanying1*
Abstract
Background: Many studies have investigated the efficacy and safety of matrine in treating malignant pleural
effusion by thoracic perfusion. This study is an analytic value of available evidence.
Methods: Twelve studies were analyzed in this study. Pooled odds ratios and hazard ratio with 95 % confidence
intervals were calculated using the fixed effects model.
Results: Overall response rate of matrine combined with other medications in treating malignant pleural effusion
(MPE) was significantly higher than those of other medications alone (p < 0.05). Time to pleural effusion relief and
quality of life were improved after the treatment of matrine combined with other medications (p < 0.05). Moreover,
matrine combined with other medications had a lower incidence of adverse reactions (p < 0.05).
Conclusions: Matrine combined with other medications improves the control of the malignant pleural effusions
and decreases the incidence of adverse reactions.
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Background
Malignant pleural effusion (MPE) poses a significant
clinical problem. In oncology patients, there are a num-
ber of common medical problems associated with the
development of pleural effusion which frequently coexist
with the malignancy. Tumor-induced impairment of
pleural fluid drainage and pertinent findings point to-
ward another pathway to MPE formation: a vicious loop
of interactions between pleural-based tumor cells and
the host vasculature and immune system that results in
increased net fluid production via enhanced plasma ex-
travasation into the pleural space [1]. As a result, pa-
tients with MPE face a limited survival of a few months,
depending on the underlying malignancy. First-line
treatment of MPE may include chemotherapy aimed at
tumor shrinkage and pleural fluid absorption. However,
most causative tumors are or become chemoresistant,
and many patients with MPE are not fit for
chemotherapy. Therefore, treatment commonly relies on
palliative measures aimed at improving quality of life [1].
Therefore, novel, effective, safe, and convenient treat-
ment modalities for patients with MPE are needed.
Nowadays, novel strategy and effective therapies that
were needed to improve outcome of these patients re-
main challenging. Nowadays, to discover and develop
novel natural compounds that have therapeutic selectiv-
ity or that can preferentially kill lung cancer cells with-
out significant toxicity to normal cells is an important
tendency for therapy of MPE. Accumulating research
evidence suggests that many medicinal plants may be
used alone or in combination with common chemother-
apeutic agents to treat MPE. Due to their wide range of
biological activities and low toxicity in animal models,
these products have been used as alternative treatments
for MPE.
Matrine is a naturally occurring small-molecule com-
pound from traditional Chinese medicine Sophora fla-
vescens Ait. In China, matrine as a clinical drug has been
used to treat cancer. The results indicated that matrine
induced the apoptosis of murine hepatoma cells in vitro
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and in vivo as well as inhibited tumor growth [2] and
also inhibited the invasiveness and metastasis of human
malignant melanoma cell line A375 [3]. Some studies re-
ported that matrine induced gastric cancer MKN45 cell
apoptosis [4] and reduced Hela cell adhesion and migra-
tion [5]. Matrine was approved by the China State Food
and Drug Administration (SFDA) for the treatment of
cancer in 1992. To date, some studies discuss the effi-
cacy and safety of murine in treating MPE by thoracic
perfusion. Whether or not matrine has the potential
therapeutic and/or adjuvant therapeutic application in
the treatment of human MPE is conflicting. This
study presents a systematic study to quantify the tox-
icities and clinical benefits of matrine combined with
other medications versus other medications alone in
treating advanced MPE.
Methods
Search strategy and data extraction
An electronic search of scientific literature published in
the databases of MEDLINE/PubMed, Embase, Cochrane
Library, Science Citation Index, and CNKI was per-
formed using free text and Medical Subject Heading
terms such as “malignant pleural effusion,” “MPE,”
“matrine,” “oxymatrine,” “matrine injection,” “kushen-
zongjian zhusheye,” “fufang kushen zhusheye,” “chemo-
therapy,” “sophora flavescens ait,” and “shrubby sophora
extract.” The search period was from the start of each
database up to May 2015 without language restrictions.
Moreover, a manual revision of the bibliographical refer-
ences of the selected articles was done. The extracted
data are summarized as follows: (1) general information,
including the title, author, publication date, and litera-
ture sources; (2) design and implementation, including
the type of design, research and follow-up time, inter-
ventions, measurement indicator, the number of lost and
processed samples; and (3) outcome indicators, includ-
ing response rate (RR), disease control rate (DCR), mean
survival time (MST), time to progression (TTP), quality
of life (QOL), and adverse effects (AEs).
Criteria for inclusion and exclusion
Inclusion criteria were as follows: (1) trials must com-
pare matrine combined with other medications to other
medications alone through thoracic perfusion; (2) pa-
tients in the studies must be diagnosed and confirmed
by cytology and pathology; (3) age and gender must not
be restricted; (4) must report on at least one of the out-
come measures mentioned in the succeeding portion of
this study; and (5) the total number of cases must be
greater than or equal to 80. The following studies were
excluded: (1) those with no clearly reported outcomes of
interest; (2) studying on animals not on human; and (3)
studies lacking control groups.
Type of trial design, interventions, and indicators to
determine efficacy
Trial design: randomized controlled trials of matrine
combined with other medications versus other medi-
cations alone in treating MPE by thoracic perfusion.
Type of interventions: matrine + other medications
vs. other medications alone; efficacy indicators: ORR,
DCR, MST, TTP, QOL, and AEs (according to the
toxicity criteria of WHO).
Methodological quality assessment
The methodological quality for RCTs was assessed
using the criteria from the Cochrane Handbook for
Systematic Reviews of Interventions (version 5.0.1).
The quality of trials was categorized into low risk of
bias, unclear risk of bias, or high risk of bias. This
categorization was according to the risk for each im-
portant outcome within included trials, including ad-
equacy of the generation of allocation sequence,
allocation concealment, blinding, and the presence of
incomplete outcome data, selective outcome, or other
sources of bias. The intention-to-treat (ITT) analysis
was also assessed for the randomized controlled trials
included into the present meta-analysis [6, 7].
Statistical analysis
To assess the efficacy and safety of matrine combined
with other medications versus other medications alone
for treating MPE, fixed effects model was performed. Di-
chotomous variables were analyzed using estimation of
odds ratios (OR) with a 95 % confidence interval (95 %
CI). The overall effect was tested using Z-scores, with
significance being set at p < 0.05. Pooled effect was cal-
culated using either the fixed effects model or random
effects model. Heterogeneity was evaluated through chi-
square and I2. Meta regression was done to evaluate
whether results were different between two groups. Sen-
sitivity was analyzed by omitting each study from the es-
timated pool conducted at each step. Finally, publication
bias was evaluated using funnel plots, the Egger’s test,
and the Begg’s test. Statistical analyses were performed
using SPSS (SPSS Institute, version 19.0, Chicago, USA),
RevMan 5.2 (The Cochrane Collaboration), and Stata
version 13.0 (Stata Corporation, TX, USA). All p values




Our systematic search identified 408 potentially relevant
abstracts, of which 122 were identified as requiring full-
text article retrieval. Close screening of these 122 studies
excluded 109 because of the following reasons: limited
cases, non-human studies, and some received matrine
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therapy without a parallel control. Finally, 12 studies2
[8–19] published between 2006 and 2014 matched the
inclusion criteria and were therefore included (Fig. 1).
Table 1 shows the baseline demographic factors of the
patients. The eligible studies included 1320 patients, and
the sample sizes oscillated between 80 [8] and 168 [15]
patients, and the age of the patients mainly concentrated
at the range of 40 to 70 years old, with the youngest at
20 years old [8] and the oldest at 85 years old [15].
Quality of study design
The studies were appraised independently by three au-
thors (Rong BX, Ma SX, and Gao WL) based on the cri-
teria from the Cochrane Handbook for Systematic
Reviews of Interventions (version 5.0.1). According to
our predefined quality assessment criteria, 9 of the 12
trials (75 %) were evaluated as having a low risk-of-bias,
and another 3 included trials were evaluated as having
an unclear risk-of-bias (25 %). Table 2 shows the quality
of each study included in the present systematic review.
Comparison of ORR between matrine combined with
other medications and other medications alone
Twelve studies compared the ORR between matrine
combined with other medications and other medications
alone for MPE. The results of the fixed effects model
showed that OR = 1.38 (95 % CI 1.17 to 1.64; test for
heterogeneity =3.78; I2 = 0 %) and test for overall ef-
fect Z = 3.04, p = 0.002. The ORR of matrine com-
bined with other medications was significantly higher
than that of with other medications alone. The sub-
group analyses showed that ORR favored the follow-
ing three matrine combinations with the overall effect
Z-value and p values as follows: cisplatin + matrine
versus cisplatin alone (Z = 1.31, p = 0.018); biological
agents (including interleukin-11 (IL-11), interleukin-2
(IL-2), а-interferon (а-IFN), and Corynebacterium par-
vum) + matrine versus biological agents alone (Z =
2.40, p = 0.016); and other chemotherapeutic agents
(including mitomycin C (MMC), bleomycin (BLM),
and hydroxycamptothecin (HCPT)) + matrine versus
chemotherapeutic agents alone (Z = 1.55, p = 0.012)
(Fig. 2). Sensitivity analyses showed that the RR and
95 % CI did not alter substantially by removing any
one trial (data not shown), with an OR pool oscillat-
ing between 0.96 and 1.88.
Comparison of QOL between matrine combined with
other medications and other medications alone
Twelve trials compared the QOL between matrine com-
bined with other medications and other medications
alone for MPE. The results of the fixed effects model
Fig. 1 Flow chart of literature search. RCTs randomized controlled trials
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Table 1 Patient characteristics of the clinical trials reviewed
Study Number of
patients
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showed that OR = 1.40 (95 % CI 1.18 to 1.66; test for
heterogeneity =1.74; I2 = 0 %) and test for overall ef-
fect Z = 3.84, p < 0.0001. Matrine combined with other
medications significantly improves the QOL of MPE
patients. The subgroup analyses showed that ORR fa-
vored the following three matrine combinations with
the overall effect Z-value and p values as follows: cis-
platin + matrine versus cisplatin alone (Z = 2.46, p =
0.014); biological agents (including IL-11, IL-2, а-IFN,
and Corynebacterium parvum) + matrine versus bio-
logical agents alone (Z = 2.48, p = 0.013); and other
chemotherapeutic agents (including MMC, BLM, and
HCPT) + matrine versus chemotherapeutic agents
alone (Z = 1.65, p = 0.100) (Fig. 3). In the analysis of
sensitivity, the exclusion of studies individually did
not substantially modify the estimators, with an OR
pool oscillating between 1.20 and 1.74.
Comparison of time to pleural effusion relief between
matrine combined with other medications and other
medications alone
Three studies reported time to pleural effusion relief,
and the results showed that the time to pleural effusion
relief (mean ± SD) of matrine combined with other med-
ications and other medications alone was 14.33 ± 1.20
and 8.33 ± 0.88 months, respectively. The t value was
4.025; the degrees of freedom was 3, p = 0.015 (Table 3).
The time to pleural effusion relief of matrine combined
arm was significantly longer than that of other medica-
tions alone (Fig. 4a).
Comparison of chest pain between matrine combined
with other medications and other medications alone
Four trials conducted a statistical analysis of the change
of chest pain between matrine combined with other
Table 1 Patient characteristics of the clinical trials reviewed (Continued)
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Abbreviations: M/F male/ female, MPE malignant pleural effusion, Group 1 matrine combined with other therapy, Group 2 other therapy alone, KPS Karnofsky
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medications and other medications alone. The result in-
dicated that the chest pain was significantly decreased
by treatment of matrine combined with other medica-
tions than that of other medications alone (p < 0.05)
(Table 4, Fig. 4b).
Adverse reactions analysis of matrine combined with
other medications and other medications alone
Included trials assessed seven serious AEs, the most
common being gastrointestinal and hematologic dis-
eases. Ten studies compared the myelotoxicity be-
tween matrine combined with other medications and
other medications alone. The matrine combination
arms had a lower incidence of myelotoxicity relative
to the other medications arms (OR = 0.49, 95 % CI
0.37 to 0.64, p < 0.0001) (Fig. 5). Nine studies
compared the damage of the liver and kidney between
matrine combined with other medications and other
medications alone. The result indicated that matrine
combined with other medications had a lower inci-
dence of the damage of the liver and kidney than
other medications alone (OR = 0.41, 95 % CI 0.31 to
0.56, p < 0.0001) (Fig. 6). Eleven studies compared
nausea/vomiting between matrine combined with
other medications and other medications alone. Other
common AEs including skin rash, nausea, vomiting,
alopecia, nerve toxicity, and mucositis occurred with
similar incidence in the two groups (p > 0.05).
Analysis of publication bias
In the present study, the shape of the funnel plot ap-
peared to be approximately symmetrical and suggested
Fig. 2 Comparison of ORR between matrine combined with other medications and other medications alone. ORR overall response rate, OR odds ratio,
P cisplatin, M murine, IL-11 interleukin-11, IL-2 interleukin-2, а-IFN а-interferon, CP Corynebacterium parvum, MMC mitomycin C, BLM bleomycin,
HCPT hydroxycamptothecin
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that publication biases may not have a significant effect
on the results. The result of the Egger’s test was t = 1.39
(p = 0.195) (Fig. 7a), whereas that of the Begg’s test was
std. dev. of score =14.58 (p = 0.086) (Fig. 7b). Therefore,
both tests suggested that publication biases may not
have a significant effect on the results.
Discussion
MPE is a common clinical problem faced by many phy-
sicians, oncologists, and thoracic surgeons. Patients with
MPE can be debilitated with dyspnea, decreased exercise
tolerance, and impaired QOL. Median survival following
the diagnosis of MPE ranges from 3 to 12 months, with
Fig. 3 Comparison of QOL between matrine combined with other medications and other medications alone. ORR overall response rate, OR odds
ratio, P cisplatin, M murine, IL-11 interleukin-11, IL-2 interleukin-2, а-IFN а-interferon, CP Corynebacterium parvum, MMC mitomycin C, BLM bleo-
mycin, HCPT hydroxycamptothecin
Table 3 Comparison of time to pleural effusion relief of matrine combined with other medications and other medications alone
Matrine combined with other medications (months) Other medications alone (months) T-value 95 % CI p value
Yunfang et al. [15] 16.4 8.2 T = 4.025 1.862 to 10.14 0.015
Daiju and Xiaodong [19] 15.98 10.06 df = 3
Liangfa et al. [11] 12.00 7.00
Mean ± SD 14.33 ± 1.20 8.33 ± 0.88
95 % CI 95 % confidence interval, SD standard deviation
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lung cancer as the primary cancer demonstrating the
shortest survival. The management options for MPE de-
pend on several factors, including patient’s symptoms,
performance status, underlying primary type, and the
potential response to anti-neoplastic therapy. The overall
aim is for the alleviation of symptoms and improved
QOL. Matrine, a kind of alkaloid components found in
the roots of Sophora species, is demonstrated to have
anti-inflammatory, anti-virus, anti-fibrotic, and cardio-
vascular protective effects. They are recently proved to
have anti-cancer potentials, such as inhibiting cancer cell
proliferation, inducing cell cycle arrest, accelerating
apoptosis, restraining angiogenesis, inducing cell differ-
entiation, inhibiting cancer metastasis and invasion, re-
versing multidrug resistance, and preventing or reducing
chemotherapy- or radiotherapy-induced toxicity when
combined with other chemotherapeutic drugs [20].
Sophora root, which is a traditional herb medicine found
in China, Japan, and some European countries, is the
dried root of Sophora flavescens Aiton (Leguminosae)
and includes matrine and oxymatrine, two major
tetracyclo-quinolizindine alkaloids, as its primary com-
ponents [20].
In recent years, some studies have reported on the
efficacy and safety of matrine in the treatment of MPE.
In this work, 12 reports of randomized trials were iden-
tified by searching from the start of each database up to
January 2015. A significant benefit of matrine plus other
medications in ORR was found (OR = 1.38, 95 % CI 1.17
to 1.64), translating into a 21 % absolute improvement.
As follows, cisplatin + matrine versus cisplatin alone,
biological agents (including IL-11, IL-2, а-IFN, and Cor-
ynebacterium parvum) + matrine versus biological
agents alone, and other chemotherapeutic agents (in-
cluding MMC, BLM, and HCPT) + matrine versus che-
motherapeutic agents alone showed improvements of
16.1, 11.7, 24, and 20 % in ORR, respectively, which indi-
cates that matrine combination therapy do better bene-
fits in treating MPE via thoracic perfusion. Three reports
analyzed that the time to pleural effusion relief of
matrine combined with other medications (14.33 ±
1.20 months) in treating MPE was significantly longer
than that of other medications alone (8.33 ±
0.88 months). Chest pain, commonly seen in pleural me-
tastasis of malignant tumors, is typically localized to the
side of the effusion and is described as dull and aching
rather than non-malignant pleuritis. In present study,
four trials indicated that the chest pain was significantly
decreased by treating of matrine combined with other
medications than that of other medications alone (p <
0.05). The relief of chest pain is an improvement of
quality of life, and it is also an important aspect of treat-
ment of patients. Matrine treatment has been shown to
inhibit the proliferation of tumor cells in various can-
cers, including gastric cancer, breast cancer, hepatoma,
colon cancer, melanoma, glioma, osteosarcoma,
Fig. 4 Comparison of time to pleural effusion relief and chest pain between matrine combined with other medications and other medications
alone. a Comparison of time to pleural effusion relief between matrine combined with other medications and other medications; b comparison
of chest pain between matrine combined with other medications and other medications alone
Table 4 Comparison of chest pain between matrine combined with other medications and other medications alone
Matrine combined with other medications (%) Other medications alone (%) T-value 95 % CI p value
Zhiwen et al. [12] 15 (33.3) 27 (60) T = 3.781 2.862 to 9.14 0.006
Xiaowei et al. [10] 4 (6) 9 (15) df = 4
Daiju and Xiaodong [19] 7 (9) 25 (33)
Li [8] 1 (2) 7 (14)
Overall incidence 27 (12) 68 (31)
95 % CI 95 % confidence interval
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pancreatic cancer, and leukemia in a dose-dependent
manner [20]. Resistance to apoptosis is a hallmark of
cancer. Studies have reported that matrine exert anti-
cancer effects by inducing apoptosis in different types of
cancers. In non-small cell lung carcinoma (NSCLC), MT
increases the phosphorylation of p38 and generates re-
active oxygen species (ROS) in a dose- and time-
dependent manner, which indicated that MT could acti-
vate p38 pathway and lead to a caspase-dependent apop-
tosis by inducing the generation of ROS [21].
Because QOL can be measured by various means, it is
also quite easy to use it to measure and predict many
variables during treatment. The benefit of chemotherapy
in incurable cancers needs to be assessed directly
through validated health-related QOL instruments ra-
ther than inferred from RRs, survival benefits, and other
traditional endpoints. In the present study, 12 trials were
enrolled in the assessment of QOL. A significant benefit
of matrine plus other medications in the overall im-
provement rate of QOL (OR = 1.40, 95 % CI 1.18 to
1.66) was found, translating into a 24 % absolute im-
provement. Thus, the results showed that matrine can
be used to relieve general side effects and improve pa-
tients’ QOL via pleural perfusion to cure MPE. The AEs
found in the present analysis were mainly hematological
reactions, diarrhea, toxicity of the liver and kidney, and
nausea/vomiting, most of which were grade 1 or 2 and
were well tolerated. The matrine combination arms had
a lower incidence of myelotoxicity and dysfunction of
the liver and kidney relative to the arms without
matrine. And the incidence of nausea/vomiting of
matrine combination arms was also significantly lower
than that of other medications alone. The results sup-
ported that the matrine combination arms had a lower
incidence of AEs compared with other medications
alone, which indicates that matrine does has a impact on
Fig. 5 Comparison of myelotoxicity between matrine combined with other medications and other medications alone. ORR overall response rate,
OR odds ratio, P cisplatin, M murine, IL-11 interleukin-11, IL-2 interleukin-2, а-IFN а-interferon, CP Corynebacterium parvum, MMC mitomycin C, BLM
bleomycin, HCPT hydroxycamptothecin
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Fig. 6 Comparison of damage of the liver and kidney between matrine combined with other medications and other medications alone. ORR
overall response rate, OR odds ratio, P cisplatin, M murine, IL-11 interleukin-11, IL-2 interleukin-2, а-IFN а-interferon, CP Corynebacterium parvum,
MMC mitomycin C, BLM bleomycin, HCPT hydroxycamptothecin
Fig. 7 Assessment of publication bias. a Egger’s publication bias plot for the ORR of matrine combined with other medication and other
medication alone; b Begg’s publication bias plot for the ORR of matrine combined with other medication and other medication alone
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improving safety of chemotherapy and relieving general
side effects. Overall, these results indicate that the po-
tential benefit of matrine may be widely applicable to a
patient population closely resembling clinical reality in
advanced MPE.
In this review, the included studies were carefully
assessed. A good clinical homogeneity was confirmed,
and publication bias was not found according to the fun-
nel plot analysis, the Egger’s test, and the Begg’s test.
However, some deficiencies in the present work were
found. First, the quality of subgroup analysis (age, sex,
smoking, histology, and treatment status) according to
the different agents (matrine plus other medications
compared with other medications alone) was low be-
cause the subgroup data were only provided by a few
trials. Second, some reports failed to report the method
for concealment of allocation, blinding, and ITT. In
addition, the partial reports comprise a small sample
size, and some of the reports’ experimental control is
not very balanced. Most of the included studies were
published in Chinese, with heterogeneous data and ana-
lysis methods (e.g., the different scored scales were used
to assess the life quality). Although such studies were re-
ported to be of low quality, they still contain credible
evidence pointing toward such new drugs. Clinical trials
are expensive and difficult. Hence, these findings can
help choose the most promising agents for study. How-
ever, matrine, as a new strategy, has still many issues to
be resolved in further studies. Confirmation of these
conclusions in rigorously controlled randomized trials is
required before firm conclusions about this therapy can
be drawn.
Conclusions
The results showed that matrine combined with other
medications was associated with higher ORR and super-
ior QOL compared with other medications alone. More-
over, matrine combination therapy was shown to
prolong the time to pleural effusion relief and decrease
the incidence rate of chest pain and other AEs. There-
fore, it indicates that matrine combination therapy ex-
hibited superior efficacy and safety. The notable efficacy
and activity of matrine in combination with other medi-
cations in treating MPE suggest that this regimen may
have a value in the treatment of patients suffering from
MPE, including those who cannot tolerate more aggres-
sive therapies. However, confirmation of these conclu-
sions in rigorously controlled randomized trials is
required before firm conclusions about this therapy can
be drawn.
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